Palvella Therapeutics, Inc. Common Stock

PVLANASDAQ • USD
ThemeBiotech - Drug Development›Rare Disease Therapeutics
108.67 USD
↘ 6.15 (5.36%)AT CLOSE (11:59 AM EDT)
108.69
↗ 0.02 (0.02%)
POST MARKET (AS OF 04:26 PM EDT)
Post Market
AS OF 04:26 PM EDT
108.69
↗ 0.02 (0.02%)
🔴Market: CLOSED
Open?$112.00
High?$114.48
Low?$105.62
Prev. Close?$114.82
Volume?374.2K
Avg. Volume?225.5K
VWAP?$109.31
Rel. Volume?1.66x
Bid / Ask
Bid?$90.30 × 100
Ask?$129.24 × 100
Spread?$38.94
Midpoint?$109.77
Valuation & Ratios
Market Cap?1.6B
Shares Out?14.3M
Float?9.0M
Float %?75.8%
P/E Ratio?N/A
P/B Ratio?6.71
EPS?-$3.44
Dividend?0.00%
Ex-Dividend?N/A

PVLA is currently priced at $108.67. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, PVLA trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Themes
Biotech - Drug Development›Rare Disease Therapeutics
Employees
29
Market Cap
1.6B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.palvellatx.com
Listed
2024-12-16
Address
353 W. LANCASTER AVENUE
WAYNE, PA 19087
Phone: (484) 253-1461
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
23
Short Sent.?
45
Piotroski F-Score?0/9Weak
Altman Z-Score?29.52Safe
Confidence?41%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?23.95%Squeeze Risk
Short Interest?2.1M
Days to Cover?8.9
Free Float9.0M
Avg Daily Volume242.1K
Settlement Date2026-05-15
Financial Health
Current Ratio?28.88Strong
Quick Ratio?28.88Strong
Cash Ratio?22.64Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
28
6.71FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-29.7CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
7
-21.3%WEAK▾
ROA?
S&P
3
-18.7%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$1.4B
Fundamentals ratios updated end of day
MarketsMoversWatchlist